Literature DB >> 11171737

Effect of a serotonin receptor antagonist on interleukin-6-induced pulmonary hypertension in rats.

M Miyata1, M Ito, T Sasajima, H Ohira, R Kasukawa.   

Abstract

STUDY
OBJECTIVES: To determine the significance of serotonin in the pathogenesis of interleukin (IL) 6-induced pulmonary hypertension (IL-6-PH) in rats, the plasma serotonin concentrations, and the effects of a specific antagonist of the serotonin (5-hydroxytryptamine [5-HT]) receptor, 1-[o-(m-methoxyphenyl)ethyl]phenoxy]-3-(dimethylamino)-2-propyl hydrogen succinate hydrochloride (MCI) on the degree of pulmonary hypertension (PH) were investigated in MCI-treated IL-6-PH (IL-6-MCI-PH) rats. MEASUREMENTS: The thickness of the media of small pulmonary arteries and the ratio of the weight of the right ventricle free wall (RV) to that of the left ventricle with the septum (LV + S) were measured as indexes of the degree of PH. Serotonin concentrations in plasma and in supernatants of cultured vascular smooth muscle cells (VSMCs) stimulated by IL-6 were measured by high-performance liquid chromatography. The amplification of DNA encoding the 5-HT receptor in the lung specimen and VSMCs was performed by polymerase chain reaction.
RESULTS: The degree of PH, as determined by the medial thickness of small pulmonary arteries, was significantly increased in IL-6-PH rats as compared with normal control rats (p<0.05), and that in IL-6-MCI-PH rats was not significantly different from that in normal control rats. The RV/LV + S weight ratio in the IL-6-PH rats was significantly higher than that in normal control rats (p < 0.01). The RV/LV + S weight ratio in IL-6-MCI-PH rats was significantly lower than that in IL-6-PH rats (p < 0.01) and was not significantly different from that in normal control rats. The serotonin concentration was significantly higher in IL-6-PH rats than in normal control rats (p < 0.02), and the serotonin concentration in IL-6-MCI-PH rats was not significantly different from that in the normal control rats. The expression levels of the 5-HT receptor messenger RNA in the lung tissue tended to increase in IL-6-PH rats but was suppressed in IL-6-MCI-PH rats. IL-6 significantly increased the amount of serotonin released from VSMCs (p < 0.02). The expression of the 5-HT receptor messenger RNA was observed with IL-6 stimulation as was observed with serotonin stimulation in VSMCs.
CONCLUSIONS: Serotonin receptor antagonists could be considered as potentially useful agents for the treatment of chronic thromboembolic PH, as well as for that of primary PH and PH associated with collagen vascular diseases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11171737     DOI: 10.1378/chest.119.2.554

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  13 in total

1.  Sarpogrelate hydrochloride, a serotonin 5HT2A receptor antagonist, ameliorates the development of chronic hypoxic pulmonary hypertension in rats.

Authors:  Erquan Zhang; Junko Maruyama; Ayumu Yokochi; Yoshihide Mitani; Hirofumi Sawada; Masakatsu Nishikawa; Ning Ma; Kazuo Maruyama
Journal:  J Anesth       Date:  2015-05-01       Impact factor: 2.078

Review 2.  Inflammasomes: a novel therapeutic target in pulmonary hypertension?

Authors:  Tara Elizabeth Scott; Barbara K Kemp-Harper; Adrian J Hobbs
Journal:  Br J Pharmacol       Date:  2018-06-27       Impact factor: 8.739

3.  Gene delivery of cytochrome p450 epoxygenase ameliorates monocrotaline-induced pulmonary artery hypertension in rats.

Authors:  Changlong Zheng; Luyun Wang; Rui Li; Ben Ma; Ling Tu; Xizhen Xu; Ryan T Dackor; Darryl C Zeldin; Dao Wen Wang
Journal:  Am J Respir Cell Mol Biol       Date:  2010-01-29       Impact factor: 6.914

Review 4.  Medical Management of Pulmonary Hypertension with Unclear and/or Multifactorial Mechanisms (Group 5): Is There a Role for Pulmonary Arterial Hypertension Medications?

Authors:  Jason Weatherald; Laurent Savale; Marc Humbert
Journal:  Curr Hypertens Rep       Date:  2017-10-18       Impact factor: 5.369

5.  Serotonin-induced growth of pulmonary artery smooth muscle requires activation of phosphatidylinositol 3-kinase/serine-threonine protein kinase B/mammalian target of rapamycin/p70 ribosomal S6 kinase 1.

Authors:  Yinglin Liu; Barry L Fanburg
Journal:  Am J Respir Cell Mol Biol       Date:  2005-09-29       Impact factor: 6.914

6.  Effects of olmesartan, an AT1 receptor antagonist, on hypoxia-induced activation of ERK1/2 and pro-inflammatory signals in the mouse lung.

Authors:  Yoshiyuki Tanabe; Yuki Morikawa; Takao Kato; Satoshi Kanai; Taichi Watakabe; Ami Nishijima; Hijiri Iwata; Kaori Isobe; Mayumi Ishizaki; Koichi Nakayama
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-11-07       Impact factor: 3.000

7.  Circulating endotoxin and interleukin-6 levels are associated with Doppler-evaluated pulmonary vascular resistance in cirrhotic patients.

Authors:  Georgios N Kalambokis; Athanasia Mouzaki; Maria Rodi; Konstantinos Pappas; Panagiotis Korantzopoulos; Epameinondas V Tsianos
Journal:  Hepatol Int       Date:  2012-02-02       Impact factor: 6.047

8.  Severe pulmonary arterial hypertension induced by SU5416 and ovalbumin immunization.

Authors:  Shiro Mizuno; Laszlo Farkas; Aysar Al Husseini; Daniela Farkas; Jose Gomez-Arroyo; Donatas Kraskauskas; Mark R Nicolls; Carlyne D Cool; Herman J Bogaard; Norbert F Voelkel
Journal:  Am J Respir Cell Mol Biol       Date:  2012-07-27       Impact factor: 6.914

9.  Interleukin-6 as a potential therapeutic target for pulmonary arterial hypertension.

Authors:  Yoshiaki Furuya; Toru Satoh; Masataka Kuwana
Journal:  Int J Rheumatol       Date:  2010-08-02

10.  Effect of thrombomodulin on the development of monocrotaline-induced pulmonary hypertension.

Authors:  Yasuharu Yamada; Junko Maruyama; Erquan Zhang; Amphone Okada; Ayumu Yokochi; Hirofumi Sawada; Yoshihide Mitani; Tatsuya Hayashi; Koji Suzuki; Kazuo Maruyama
Journal:  J Anesth       Date:  2013-07-02       Impact factor: 2.078

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.